About this Journal Submit a Manuscript Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 150478, 8 pages
http://dx.doi.org/10.1155/2013/150478
Research Article

Enhanced Oral Delivery of Docetaxel Using Thiolated Chitosan Nanoparticles: Preparation, In Vitro and In Vivo Studies

1Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran 1417614411, Iran
2R&D Department, Osvah Pharmaceutical Co., Tehran, Iran
3Nanotechnology Research Centre, Tehran University of Medical Sciences, Tehran 1417614411, Iran
4Department of Toxicology and Pharmacology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

Received 4 April 2013; Revised 23 June 2013; Accepted 24 June 2013

Academic Editor: Frederic Lagarce

Copyright © 2013 Shahrooz Saremi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. F. Escobar and P. G. Rose, “Docetaxel in ovarian cancer,” Expert Opinion on Pharmacotherapy, vol. 6, no. 15, pp. 2719–2726, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. K. Iwao-Koizumi, R. Matoba, N. Ueno et al., “Prediction of docetaxel response in human breast cancer by gene expression profiling,” Journal of Clinical Oncology, vol. 23, no. 3, pp. 422–431, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. W. Eiermann, “Docetaxel-maximising outcomes towards cure in early breast cancer,” Breast, vol. 15, supplement 3, pp. S13–S16, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. K. Gelmon, “The taxoids: paclitaxel and docetaxel,” The Lancet, vol. 344, no. 8932, pp. 1267–1272, 1994. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Aapro, “The scientific rationale for developing taxoids,” Anti-Cancer Drugs, vol. 7, no. 2, pp. 33–36, 1996. View at Scopus
  6. S. Jones, “Head-to-head: docetaxel challenges paclitaxel,” European Journal of Cancer, vol. 4, no. 4, pp. 4–8, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. I. E. L. M. Kuppens, T. M. Bosch, M. J. Van Maanen et al., “Oral bioavailability of docetaxel in combination with OC144-093 (ONT-093),” Cancer Chemotherapy and Pharmacology, vol. 55, no. 1, pp. 72–78, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Shou, M. Martinet, K. R. Korzekwa, K. W. Krausz, F. J. Gonzalez, and H. V. Gelboin, “Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: enzyme specificity, interindividual distribution and metabolic contribution in human liver,” Pharmacogenetics, vol. 8, no. 5, pp. 391–401, 1998. View at Publisher · View at Google Scholar · View at Scopus
  9. M. M. Malingré, J. H. Beijnen, and J. H. M. Schellens, “Oral delivery of taxanes,” Investigational New Drugs, vol. 19, no. 2, pp. 155–162, 2001. View at Publisher · View at Google Scholar · View at Scopus
  10. L. Van Zuylen, J. Verweij, and A. Sparreboom, “Role of formulation vehicles in taxane pharmacology,” Investigational New Drugs, vol. 19, no. 2, pp. 125–141, 2001. View at Publisher · View at Google Scholar · View at Scopus
  11. M. M. Malingré, D. J. Richel, J. H. Beijnen et al., “Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel,” Journal of Clinical Oncology, vol. 19, no. 4, pp. 1160–1166, 2001. View at Scopus
  12. M. Malingré, J. H. M. Schellens, O. Van Tellingen et al., “Metabolism and excretion of paclitaxel after oral administration in combination with cyclosporin A and after i.v. administration,” Anti-Cancer Drugs, vol. 11, no. 10, pp. 813–820, 2000. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Yousefi, F. Esmaeili, S. Rahimian, F. Atyabi, and R. Dinarvand, “Preparation and in vitro evaluation of a pegylated nano-liposomal formulation containing docetaxel,” Scientia Pharmaceutica, vol. 77, no. 2, pp. 453–464, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. M. L. Immordino, P. Brusa, F. Rocco, S. Arpicco, M. Ceruti, and L. Cattel, “Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs,” Journal of Controlled Release, vol. 100, no. 3, pp. 331–346, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. Y.-M. Yin, F. Cui, C. Mu et al., “Docetaxel microemulsion for enhanced oral bioavailability: preparation and in vitro and in vivo evaluation,” Journal of Controlled Release, vol. 140, no. 2, pp. 86–94, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. K. Gao, J. Sun, K. Liu, X. Liu, and Z. He, “Preparation and characterization of a submicron lipid emulsion of docetaxel: submicron lipid emulsion of docetaxel,” Drug Development and Industrial Pharmacy, vol. 34, no. 11, pp. 1227–1237, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. J. Kim, Y. Kim, S. Kim et al., “Hydrophobically modified glycol chitosan nanoparticles as carriers for paclitaxel,” Journal of Controlled Release, vol. 111, no. 1-2, pp. 228–234, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. F. Esmaeili, R. Dinarvand, M. H. Ghahremani, S. N. Ostad, H. Esmaily, and F. Atyabi, “Cellular cytotoxicity and in-vivo biodistribution of docetaxel poly(lactide-co-glycolide) nanoparticles,” Anti-Cancer Drugs, vol. 21, no. 1, pp. 43–52, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. Y. Dong and S. Feng, “Poly(D,L-lactide-co-glycolide)/montmorillonite nanoparticles for oral delivery of anticancer drugs,” Biomaterials, vol. 26, no. 30, pp. 6068–6076, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. T. Nassar, S. Attili-Qadri, O. Harush-Frenkel et al., “High plasma levels and effective lymphatic uptake of docetaxel in an orally available nanotransporter formulation,” Cancer Research, vol. 71, no. 8, pp. 3018–3028, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. H. Chen, Y. Zheng, G. Tian et al., “Oral delivery of DMAB-modified docetaxel-loaded PLGA-TPGS nanoparticles for cancer chemotherapy,” Nanoscale Research Letters, vol. 6, no. 1, pp. 1–10, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. E. Lee, H. Kim, I. Lee, and S. Jon, “In vivo antitumor effects of chitosan-conjugated docetaxel after oral administration,” Journal of Controlled Release, vol. 140, no. 2, pp. 79–85, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. F. Esmaeili, R. Dinarvand, M. H. Ghahremani et al., “Docetaxel-albumin conjugates: preparation, in vitro evaluation and biodistribution studies,” Journal of Pharmaceutical Sciences, vol. 98, no. 8, pp. 2718–2730, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. A. T. Florence, A. M. Hillery, N. Hussain, and P. U. Jani, “Nanoparticles as carriers for oral peptide absorption: studies on particle uptake and fate,” Journal of Controlled Release, vol. 36, no. 1-2, pp. 39–46, 1995. View at Publisher · View at Google Scholar · View at Scopus
  25. Y. H. Lin, C. Chen, H. Liang et al., “Novel nanoparticles for oral insulin delivery via the paracellular pathway,” Nanotechnology, vol. 18, no. 10, Article ID 105102, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. S. Peltier, J. Oger, F. Lagarce, W. Couet, and J. Benoît, “Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded lipid nanocapsules,” Pharmaceutical Research, vol. 23, no. 6, pp. 1243–1250, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Agüeros, V. Zabaleta, S. Espuelas, M. A. Campanero, and J. M. Irache, “Increased oral bioavailability of paclitaxel by its encapsulation through complex formation with cyclodextrins in poly(anhydride) nanoparticles,” Journal of Controlled Release, vol. 145, no. 1, pp. 2–8, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Roldo, M. Hornof, P. Caliceti, and A. Bernkop-Schnürch, “Mucoadhesive thiolated chitosans as platforms for oral controlled drug delivery: synthesis and in vitro evaluation,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 57, no. 1, pp. 115–121, 2004. View at Publisher · View at Google Scholar · View at Scopus
  29. V. M. Leitner, D. Guggi, A. H. Krauland, and A. Bernkop-Schnärch, “Nasal delivery of human growth hormone: in vitro and in vivo evaluation of a thiomer/glutathione microparticulate delivery system,” Journal of Controlled Release, vol. 100, no. 1, pp. 87–95, 2004. View at Publisher · View at Google Scholar · View at Scopus
  30. F. Atyabi, F. A. Moghaddam, R. Dinarvand, M. J. Zohuriaan-Mehr, and G. Ponchel, “Thiolated chitosan coated poly hydroxyethyl methacrylate nanoparticles: synthesis and characterization,” Carbohydrate Polymers, vol. 74, no. 1, pp. 59–67, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. J. Hombach, H. Hoyer, and A. Bernkop-Schnürch, “Thiolated chitosans: development and in vitro evaluation of an oral tobramycin sulphate delivery system,” European Journal of Pharmaceutical Sciences, vol. 33, no. 1, pp. 1–8, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. F. A. Moghaddam, F. Atyabi, and R. Dinarvand, “Preparation and in vitro evaluation of mucoadhesion and permeation enhancement of thiolated chitosan-pHEMA core-shell nanoparticles,” Nanomedicine, vol. 5, no. 2, pp. 208–215, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. F. Atyabi, F. Talaie, and R. Dinarvand, “Thiolated Chitosan nanoparticles as an oral delivery system for amikacin: in vitro and ex vivo evaluations,” Journal of Nanoscience and Nanotechnology, vol. 9, no. 8, pp. 4593–4603, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. S. Saremi, F. Atyabi, S. P. Akhlaghi, S. N. Ostad, and R. Dinarvand, “Thiolated chitosan nanoparticles for enhancing oral absorption of docetaxel: preparation, in vitro and ex vivo evaluation,” International Journal of Nanomedicine, vol. 6, no. 1, pp. 119–128, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. S. P. Akhlaghi, S. Saremi, S. N. Ostad, R. Dinarvand, and F. Atyabi, “Discriminated effects of thiolated chitosan-coated pMMA paclitaxel-loaded nanoparticles on different normal and cancer cell lines,” Nanomedicine, vol. 6, no. 5, pp. 689–697, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. S. Saremi, F. Atyabi, S. P. Akhlaghi, S. N. Ostad, and R. Dinarvand, “Thiolated chitosan nanoparticles for enhancing oral absorption of docetaxel: preparation, in vitro and ex vivo evaluation,” International Journal of Nanomedicine, vol. 6, no. 1, pp. 119–128, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. C. Chauvierre, D. Labarre, P. Couvreur, and C. Vauthier, “Radical emulsion polymerization of alkylcyanoacrylates initiated by the redox system dextran-cerium(IV) under acidic aqueous conditions,” Macromolecules, vol. 36, no. 16, pp. 6018–6027, 2003. View at Publisher · View at Google Scholar · View at Scopus
  38. M. A. Arangoa, G. Ponchel, A. M. Orecchioni, M. J. Renedo, D. Duchêne, and J. M. Irache, “Bioadhesive potential of gliadin nanoparticulate systems,” European Journal of Pharmaceutical Sciences, vol. 11, no. 4, pp. 333–341, 2000. View at Publisher · View at Google Scholar · View at Scopus
  39. A. Bernkop-Schnürch, M. Hornof, and T. Zoidl, “Thiolated polymers-thiomers: synthesis and in vitro evaluation of chitosan-2-iminothiolane conjugates,” International Journal of Pharmaceutics, vol. 260, no. 2, pp. 229–237, 2003. View at Publisher · View at Google Scholar · View at Scopus
  40. A. Sadeghi, F. A. Dorkoosh, M. R. Avadi et al., “Permeation enhancer effect of chitosan and chitosan derivatives: comparison of formulations as soluble polymers and nanoparticulate systems on insulin absorption in Caco-2 cells,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 70, no. 1, pp. 270–278, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. I. Bravo-Osuna, G. Ponchel, and C. Vauthier, “Tuning of shell and core characteristics of chitosan-decorated acrylic nanoparticles,” European Journal of Pharmaceutical Sciences, vol. 30, no. 2, pp. 143–154, 2007. View at Publisher · View at Google Scholar · View at Scopus
  42. F. Chen, Z. Zhang, F. Yuan, X. Qin, M. Wang, and Y. Huang, “In vitro and in vivo study of N-trimethyl chitosan nanoparticles for oral protein delivery,” International Journal of Pharmaceutics, vol. 349, no. 1-2, pp. 226–233, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. Z. Ma and L. Lim, “Uptake of Chitosan and associated insulin in caco-2 cell monolayers: a comparison between Chitosan molecules and Chitosan nanoparticles,” Pharmaceutical Research, vol. 20, no. 11, pp. 1812–1819, 2003. View at Publisher · View at Google Scholar · View at Scopus
  44. P. Artursson, T. Lindmark, S. S. Davis, and L. Illum, “Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2),” Pharmaceutical Research, vol. 11, no. 9, pp. 1358–1361, 1994. View at Publisher · View at Google Scholar · View at Scopus
  45. J. Smith, E. Wood, and M. Dornish, “Effect of Chitosan on epithelial cell tight junctions,” Pharmaceutical Research, vol. 21, no. 1, pp. 43–49, 2004. View at Publisher · View at Google Scholar · View at Scopus
  46. E. K. Anderberg, C. Nystrom, and P. Artursson, “Epithelial transport of drugs in cell culture. VII: effects of pharmaceutical surfactant excipients and bile acids on transepithelial permeability in monolayers of human intestinal epithelial (Caco-2) cells,” Journal of Pharmaceutical Sciences, vol. 81, no. 9, pp. 879–887, 1992. View at Publisher · View at Google Scholar · View at Scopus
  47. Y. Dong and S. Feng, “Poly(D,L-lactide-co-glycolide)/montmorillonite nanoparticles for oral delivery of anticancer drugs,” Biomaterials, vol. 26, no. 30, pp. 6068–6076, 2005. View at Publisher · View at Google Scholar · View at Scopus